A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) In Patients with Manifest Huntington's Disease

  • Mathers, Susan (Primary Chief Investigator (PCI))

Project: Research

Project Details

Project Description

NMA HREC Ref Number: HREC/18/WMEAD/498 (ERM Project ID 52341)
NMA SSA Reference Number: SSA/52341/MonH-2019-175434(v1)
Monash Health Ref: RES-19-0000-404X
StatusRelinquished
Effective start/end date20/06/19 → 12/09/19

Keywords

  • clinical trial
  • phase 3 study
  • treatment efficacy
  • Huntington's disease